The European AI Act: Potential Implications for Clinical Trials
Join us for a LinkedIn Live session titled “The European AI Act: Making Sense of its Impact on Clinical Trials.”
Session information:
Time:
- 9:00 a.m. – 9:30 a.m. ET (NA-East)
- 14:00 – 14:30 GMT (UK)
- 15:00 – 15:30 CET (EU-Central)
Overview: Our experts will discuss key considerations for the use of Artificial Intelligence (AI) in clinical trials, how Clario is approaching compliance with the new EU AI Act, and what guidelines are shaping the future of AI in healthcare and clinical research. Additional topics will include:
- AI-related risk assessment considerations for clinical trials
- Steps in Clario’s responsible AI development and use process
- Real use cases that demonstrate how Clario is approaching compliance with the new EU AI Act
Speakers
Lauren Misztal
SVP and General Counsel at Clario
Lauren Misztal is Clario’s SVP and General Counsel. She sets and implements the Company’s global legal strategy and leads the data privacy, commercial contracting, and corporate legal teams. Lauren is a respected thought leader on AI governance, author of Clario’s AI Responsible Use Principles, and founding member of the Company’s AI Governance Committee.
Marko Topalovic, Ph.D.
Chief AI Officer at Clario
Marko Topalovic was the CEO and co-founder of ArtiQ, a spin-off from the Belgian university KU Leuven, and a leading developer of artificial intelligence tools used to diagnose and monitor patients with respiratory conditions. After Clario acquired ArtiQ in early 2024, Marko became Clario’s first ever Chief AI Officer.